الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 142 |  |  |
| | | from | 142 | | |
Abstract
Transfusion of platelets (PLTs) has been shown to play an important role in in the treatment of hemorrhagic conditions. Currently, PLTs are stored at room temperature (RT; 20-24°C) with gentle agitation for only 5 days due to bacterial growth concerns. As a result, alternative methods of storage to extend PLT function and prolong shelf life are needed.
PASs have been marketed since the 1980s and are utilized extensively in Europe; storage in PAS requires some plasma carryover (approx. 35%) to maintain PLT viability. It provides metabolic support and buffering so PCs shelf life can be extended.
Cold storage (1-6°C) of PLTs for up to 3 days is currently approved by the Food and Drug Administration (FDA) for use in the resuscitation of actively bleeding patients and represents a viable alternative to RT storage. Several groups have reported superior hemostatic efficacy of cold stored PLTs over RT PLTs in clinical studies. Although PLTs can be cold stored in plasma, an increased risk of PLT clumping during storage due to activation of the glycoprotein (GP) IIb/IIIa receptor and fibrinogen binding can result in a high discard rate. So, cold storage of PLTs in a PLT additive solution (PAS) could minimize cold PLT clumping by dilution of plasma fibrinogen while preserving PLT function.
In this study, we aimed to investigate the in vitro impact of cold storage on apheresis platelet concentrates with and without adding platelet additive solution and to evaluate its therapeutic utility in oncology patients.